MYGN
$12.93
Myriad Genetics
$.39
3.11%
MYGN
Earnings Whisper ®
N/A
1st Quarter September 2020
Consensus:  ($0.42)
Revenue:  $134.62 Mil
Thursday
Nov 12
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MYGN reports earnings?
Beat
Meet
Miss

Where is MYGN's stock price going from here?
Up
Flat
Down
Stock chart of MYGN
Analysts
Summary of analysts' recommendations for MYGN
Score
Grade
Pivots
Resistance
$13.82
$13.41
$13.17

$12.76

Support
$12.52
$12.11
$11.87
Tweet
Growth
Description
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
Peers
ImmunomedicsCareDxQuidelMeridian BioscienceSurModics